Comparing of Avadel Pharmaceuticals plc (AVDL) and Auris Medical Holding AG (NASDAQ:EARS)

Both Avadel Pharmaceuticals plc (NASDAQ:AVDL) and Auris Medical Holding AG (NASDAQ:EARS) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Avadel Pharmaceuticals plc 117.10M 0.53 39.69M -1.14 0.00
Auris Medical Holding AG N/A 0.00 N/A -1.92 0.00

Table 1 demonstrates Avadel Pharmaceuticals plc and Auris Medical Holding AG’s gross revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Avadel Pharmaceuticals plc -33.89% -50.1% -13.6%
Auris Medical Holding AG 0.00% 630.2% -100.9%

Volatility & Risk

A 1.79 beta means Avadel Pharmaceuticals plc’s volatility is 79.00% more than S&P 500’s volatility. Auris Medical Holding AG’s -0.56 beta is the reason why it is 156.00% less volatile than S&P 500.

Liquidity

3.1 and 3 are the respective Current Ratio and a Quick Ratio of Avadel Pharmaceuticals plc. Its rival Auris Medical Holding AG’s Current and Quick Ratios are 0.9 and 0.9 respectively. Avadel Pharmaceuticals plc has a better chance of clearing its pay short and long-term debts than Auris Medical Holding AG.

Institutional & Insider Ownership

The shares of both Avadel Pharmaceuticals plc and Auris Medical Holding AG are owned by institutional investors at 56.4% and 9% respectively. Avadel Pharmaceuticals plc’s share held by insiders are 0.3%. On the other hand, insiders held about 16.57% of Auris Medical Holding AG’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Avadel Pharmaceuticals plc -0.98% -27.34% -33.11% -57.11% -75.66% -21.71%
Auris Medical Holding AG 6.21% -10.45% -35.91% 35% -84.87% -17.11%

For the past year Avadel Pharmaceuticals plc’s stock price has bigger decline than Auris Medical Holding AG.

Summary

On 5 of the 9 factors Avadel Pharmaceuticals plc beats Auris Medical Holding AG.

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The companyÂ’s owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection. The company also provides Karbinal ER, an H1 receptor antagonist used to treat children with seasonal and perennial allergic rhinitis; AcipHex Sprinkle for the treatment of gastroesophageal reflux disease; Flexichamber, a collapsible holding chamber that administers aerosolized medication from pressurized metered dose inhalers; and Cefaclor for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections. In addition, its product candidates comprise sodium oxybate for narcolepsy; Hydromorphone/Trigger Lock for pain; Exenatide, a Medusa-based injectable formulation for diabetes; and LiquiTime for cough/cold. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. The company is also developing AM-125 for the treatment of vestibular disorders; and other pre-clinical stage products comprising AM-102 and AM-123. It has a collaboration and license agreement with Xigen S.A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders. The company was formerly known as Auris Medical AG and changed its name to Auris Medical Holding AG in April 2014. Auris Medical Holding AG was founded in 1998 and is headquartered in Zug, Switzerland.